U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

Abstract

The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and consultation with national experts who met in Atlanta, Georgia, during August 26-28, 2015. The information in this report updates the 2010 U.S. MEC (CDC. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR 2010:59 [No. RR-4]). Notable updates include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John's wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breastfeeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. The recommendations in this report are intended to assist health care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health care providers should always consider the individual clinical circumstances of each person seeking family planning services. This report is not intended to be a substitute for professional medical advice for individual patients. Persons should seek advice from their health care providers when considering family planning options.

Contraceptive Use Among Nonpregnant and Postpartum Women at Risk for Unintended Pregnancy, and Female High School Students, in the Context of Zika Preparedness — United States, 2011–2013 and 2015

“…LARC methods are highly effective, reversible methods for reducing unintended pregnancy, do not depend on user compliance, and are medically appropriate for most female adolescents and adult women (4,8). Nationally, although use of LARC methods nearly doubled in recent years (9), use remains lower than that of other reversible contraceptives such as oral contraceptive pills and condoms (9), and considerable barriers to access and contraceptive method availability remain (10).…”

Obstetric Management of a Pregnant With Type I Diabetes and Poor Metabolic Control - A Case Report

“…Maternal benefits include increased insulin sensitivity and weight loss [9]. TID without vascular disease are eligible for the use of any contraceptive method [20].…”

Long-Acting Reversible Contraception

“…Exceptions include women who have hypersensitivity to copper, which would preclude the use of the copper-containing IUD, or hypersensitivity to other components of either type of IUD; women with a current pelvic infection or a sexually transmitted disease (STD); women with gynecologic cancers; and women with certain other serious medical conditions (Table 1). 17 Women who have current purulent cervicitis or known chlamydial infection or gonococcal infection should not undergo insertion of an IUD. Women generally do not require screening for STDs at the time of IUD insertion if they have already…”